VORICONAZOL DR. REDDY'S 50 mg Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

voriconazol dr. reddy's 50 mg

dr. reddy's laboratories romania s.r.l. - voriconazolum - compr. film. - 50mg - antimicotice de uz sistemic derivati de triazol

PEMETREXED DR. REDDY'S 500 mg Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pemetrexed dr. reddy's 500 mg

dr. reddy's laboratories romania s.r.l. - pemetrexedum - pulb. pt. conc. pt.sol. perf. - 500mg - antimetaboliti analogi ai acidului folic

MEMANTINA DR. REDDY'S 10 mg Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

memantina dr. reddy's 10 mg

dr. reddy's laboratories romania s.r.l. - memantinum - compr. film. - 10mg - medicamente pentru tratamentul dementei alte medicamente pentru tratamentul dementei

Zoledronic acid Dr. Reddy’s 4 mg/5 ml concentrate for solution for infusion Velká Británie - angličtina - myHealthbox

zoledronic acid dr. reddy’s 4 mg/5 ml concentrate for solution for infusion

dr. reddy’s laboratories (uk) ltd., 6 riverview road - zoledronic acid (as monohydrate) - concentrate for solution for infusion - 4 mg for 5ml - drugs affecting bone structure and mineralization, bisphosphonates - it is used for prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. and for the treatment of adult patients with tumour-induced hypercalcaemia (tih)

Azacitidine Dr Reddy's Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

azacitidine dr reddy's

dr reddy's new zealand limited - azacitidine 100mg - powder for injection - 100 mg - active: azacitidine 100mg excipient: mannitol - azacitidine is indicated for the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukaemia (cmmol [10-29 percent marrow blasts without myeloproliferative disorder]), and acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.